Harvard Bioscience (HBIO) Competitors

Bionano Genomics (NASDAQ:BNGO) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Which has higher valuation & earnings, BNGO or HBIO?

Harvard Bioscience has higher revenue and earnings than Bionano Genomics. Harvard Bioscience is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$36.12M	1.79	-$232.49M	-$6.02	-0.16
Harvard Bioscience	$106.79M	1.29	-$3.41M	-$0.20	-15.85

Does the media prefer BNGO or HBIO?

In the previous week, Harvard Bioscience had 11 more articles in the media than Bionano Genomics. MarketBeat recorded 14 mentions for Harvard Bioscience and 3 mentions for Bionano Genomics. Harvard Bioscience's average media sentiment score of 1.01 beat Bionano Genomics' score of 0.15 indicating that Bionano Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bionano Genomics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harvard Bioscience	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do analysts prefer BNGO or HBIO?

Bionano Genomics currently has a consensus price target of $4.00, indicating a potential upside of 313.22%. Given Harvard Bioscience's higher probable upside, equities analysts clearly believe Bionano Genomics is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Harvard Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Which has more risk & volatility, BNGO or HBIO?

Bionano Genomics has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500.

Do insiders & institutionals believe in BNGO or HBIO?

11.4% of Bionano Genomics shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 1.7% of Bionano Genomics shares are held by company insiders. Comparatively, 9.0% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community favor BNGO or HBIO?

Harvard Bioscience received 206 more outperform votes than Bionano Genomics when rated by MarketBeat users. Likewise, 72.02% of users gave Harvard Bioscience an outperform vote while only 64.80% of users gave Bionano Genomics an outperform vote.

Company	Underperform	Outperform
Bionano Genomics	Outperform Votes 162 64.80%	Underperform Votes 88 35.20%
Harvard Bioscience	Outperform Votes 368 72.02%	Underperform Votes 143 27.98%

Is BNGO or HBIO more profitable?

Harvard Bioscience has a net margin of -8.18% compared to Harvard Bioscience's net margin of -605.26%. Bionano Genomics' return on equity of 0.26% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-605.26%	-129.31%	-80.29%
Harvard Bioscience	-8.18%	0.26%	0.14%

Summary

Harvard Bioscience beats Bionano Genomics on 11 of the 17 factors compared between the two stocks.